For the Inventor, By the Inventor

Enter assignee name

Calgary, Canada

Stem Cell Therapeutics Inc.

USPTO Granted Patents = 22

% Expired Patents = 90.9

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 171

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Samuel Weiss (19 out of 37 patents)

Christopher Gregg (9 out of 9 patents)

Tetsuro Shingo (6 out of 6 patents)

4. Emeka Enwere (3 out of 3 patents)

5. Linda Andersen (3 out of 3 patents)

6. Joseph Tucker (3 out of 3 patents)

7. Andrew K Chojnacki (2 out of 2 patents)

8. Bradley G Thompson (2 out of 151 patents)

9. Allen Davidoff (1 out of 6 patents)

10. Shigeki Ohta (1 out of 2 patents)

11. Peter M Wong (1 out of 1 patent)

12. Siu-Wah Chung (1 out of 1 patent)

13. Xiaodong Han (1 out of 1 patent)

14. Christopher Gregg (0 patent)

15. Christopher Gregg (0 patent)

22 patents: Sort by Forward Citations

1. 8470777 - Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin (2013-06-25),

2. 8435949 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2013-05-07),

3. 8343920 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds (2013-01-01),

4. 8333974 - Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents (2012-12-18),

5. 8222212 - Prolactin induced increase in neural stem cell numbers (2012-07-17),

6. 8217002 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2012-07-10),

7. 8143220 - Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders (2012-03-27),

8. 7994131 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds (2011-08-09),

9. 7964563 - Oligodendrocyte precursor cell proliferation regulated by prolactin (2011-06-21),

10. 7943376 - Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells (2011-05-17),

11. 7884072 - Prolactin induced increase in neural stem cell numbers (2011-02-08),

12. 7846898 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2010-12-07),

13. 7704737 - Oligodendrocyte production from multipotent neural stem cells (2010-04-27),

14. 7629169 - Methods for the production of platelet-derived growth factor-responsive neural precursor cells (2009-12-08),

15. 7604993 - Combined regulation of neural cell production (2009-10-20),

Company Overview

Stem Cell Therapeutics Inc. is a biotechnology company based in Calgary, Canada, focused on the development of innovative therapies utilizing stem cell technology. The organization specializes in research aimed at treating various medical conditions through regenerative medicine, leveraging the unique properties of stem cells to promote healing and recovery. With a commitment to advancing scientific understanding and therapeutic applications, Stem Cell Therapeutics is positioned at the forefront of the evolving landscape of cellular therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

22 Patents

#48 in Calgary

#652 in Canada

#28,807 in the World

Calgary, Canada

Stem Cell Therapeutics Inc.

Forward Citations = 171

13 inventors:

Samuel Weiss (19 out of 37 patents)

Christopher Gregg (9 out of 9 patents)

Tetsuro Shingo (6 out of 6 patents)

4. Emeka Enwere (3 out of 3 patents)

5. Linda Andersen (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Stem Cell Therapeutics Inc.. Retrieved from https://idiyas.com/company/stem-cell-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…